Clinical trial suspensions rocket in the wake of Covid-19
An across-the-board clinical trial registry analysis spells out the effect of measures to slow the spread of the new coronavirus.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Blueprint’s voyage ends in disaster
The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Biotech’s balancing act amid Covid-19 delays
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Clinical trial delays become reality as Covid-19 risk spreads
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Setback lays bare Novo’s need in haemophilia
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
